Jane Street’s Janux Therapeutics JANX Stock Holding History

Jane Street’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.02M	Buy	391,991 +140,251	+56%	+$2.03M	﹤0.01%	3448
2026 Q1	$3.5M	Sell	251,740 -288,493	-53%	-$3.96M	﹤0.01%	4080
2025 Q4	$7.46M	Buy	540,233 +458,911	+564%	+$10.8M	﹤0.01%	2685
2025 Q3	$1.99M	Buy	81,322 +47,509	+141%	+$1.16M	﹤0.01%	4952
2025 Q2	$781K	Buy	+33,813	New	+$891K	﹤0.01%	6069
2025 Q1	–	Sell	-3,814	Closed	-$144K	–	10022
2024 Q4	$204K	Sell	3,814 -35,344	-90%	-$1.87M	﹤0.01%	8377
2024 Q3	$1.78M	Sell	39,158 -408	-1%	-$17.8K	﹤0.01%	4729
2024 Q2	$1.66M	Buy	39,566 +19,434	+97%	+$912K	﹤0.01%	4827
2024 Q1	$758K	Buy	+20,132	New	+$438K	﹤0.01%	5924
2023 Q3	–	Sell	-14,935	Closed	-$177K	–	9011
2023 Q2	$177K	Buy	+14,935	New	+$200K	﹤0.01%	7733
2022 Q1	–	Sell	-15,746	Closed	-$311K	–	10671
2021 Q4	$311K	Buy	+15,746	New	+$330K	﹤0.01%	8101

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Jane Street's JANX Position: Q2 2026 in Review

Jane Street increased its Janux Therapeutics (JANX) stake by 56% in Q2 2026, buying an estimated $2.03M and bringing the position to 391,991 shares worth $6.02M. The position accounts for ﹤0.01% of the portfolio, ranked #3448.

Jane Street first reported a position in JANX in Q4 2021 and has held it in 11 quarters since. The position peaked at $7.46M in Q4 2025. 198 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

Jane Street held 391,991 shares of Janux Therapeutics worth $6.02M as of Q2 2026.
Jane Street bought 140,251 Janux Therapeutics shares in Q2 2026, an estimated $2.03M.
Janux Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #3448 holding.
Jane Street first reported a position in Janux Therapeutics in Q4 2021 and has held it in 11 quarters since.
Jane Street's Janux Therapeutics position peaked at $7.46M in Q4 2025.
198 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.